Clinical trials: Sacubitril/Valsartan
Hypertension
Sacubitril/Allisartan for Hypertensive Patients With Overweight or Obesity
To compare the efficacy and safety of sacubitril/Allisartan versus amlodipine in the antihypertensive treatment of overweight/obese patients with primary hypertension
- Trial name
- SHOT (NCT07241338)
- Testing
- sacubitril/allisartan, Amlodipine
- Where
- China
- Volunteers
- 104 people
- Sponsor
- Jing Liu
Heart Failure With Preserved Ejection Fraction, Functional Mitral Regurgitation
Sacubitril-Valsartan in Heart Failure With Preserved Ejection Fraction and Secondary Mitral Valve Regurgitation
The main objective of this study is to assess the hemodynamic effects of sacubitril-valsartan in patients with heart failure with preserved ejection fraction and at least moderate atrial functional mitral regurgitation (AFMR)…
- Trial name
- PRAISE-MR (NCT05991284)
- Testing
- Sacubitril-valsartan, Standard of care
- Where
- Belgium
- Volunteers
- 84 people
- Sponsor
- Ziekenhuis Oost-Limburg
Heart Failure
The Effects of Sacubitril/Valsartan Compared to Valsartan on LV Remodelling in Asymptomatic LV Systolic Dysfunction After MI
Prior to reperfusion therapy, the major therapeutic breakthrough in myocardial infarction was the demonstration that ACE inhibitors or ARBs, given to prevent adverse "remodelling" (progressive dilatation and decline in systolic…
- Trial name
- RECOVER-LV (NCT03552575)
- Testing
- sacubitril/valsartan, Valsartan
- Where
- 2 sites in United Kingdom
- Volunteers
- 93 people
- Sponsor
- NHS Greater Glasgow and Clyde
Heart Failure
Sacubitril/Valsartan in Heart Failure With Reduced Ejection Fraction Patients: a Real World Study in India
This was a non-interventional, retrospective EMR analysis of longitudinal prescriptions in India for a period of 1.5 years. Demographic profile of patients with heart failure with reduced ejection fraction on sacubitril/valsartan…
- Trial name
- NCT04735354
- Testing
- sacubitril/valsartan
- Where
- India
- Volunteers
- 268 people
- Sponsor
- Novartis Pharmaceuticals
Left Ventricular Diastolic Function
Impact of Sacubitril/Valsartan on LV Diastolic Function in HFrEF
This prospective cohort study evaluates the effects of six months of sacubitril/valsartan (ARNI) therapy on left ventricular diastolic function in patients with heart failure with reduced ejection fraction (HFrEF) using…
- Trial name
- NCT07157527
- Volunteers
- 70 people
- Sponsor
- Assiut University
Heart Failure, Essential Hypertension
LCZ696 in Advanced LV Hypertrophy and HFpEF
Patients with advanced LVH and HFpEF will be randomly assigned in open-label fashion to receive LCZ696 titrated to 200 mg twice daily or valsartan titrated to 160 mg twice daily, and will be treated for 24 weeks.
- Trial name
- NCT03928158
- Testing
- LCZ 696, Valsartan
- Where
- Russia
- Volunteers
- 61 people
- Sponsor
- National Medical Research Center for Cardiology, Ministry of Health of Russian Federation
Heart Failure With Reduced Ejection Fraction (HFrEF), Sacubitril/Valsartan
Evaluating Dashboard-Integrated Pharmacist-Led Education on Improving Sacubitril/Valsartan Adherence in Heart Failure (PharmD ASSIST HFrEF)
The goal of this pragmatic clinical trial is to evaluate whether pharmacist-led education, integrated with interactive visualization dashboards, can enhance medication adherence in patients with heart failure who are prescribed…
- Conditions
- Heart Failure With Reduced Ejection Fraction (HFrEF), Sacubitril/Valsartan, Medication Adherence
- Trial name
- NCT06900803
- Testing
- interactive visualization dashboard (the Enhancing Sacubitril/valsartan Adherence from Initiation to Continuation [ESAIC] dashboard)
- Volunteers
- 200 people
- Sponsor
- National Taiwan University Hospital
HIV/AIDS, Heart Failure With Preserved Ejection Fraction
The ENCHANTMENT HIV Study
Persons with HIV, even those well-treated, are at increased risk for heart disease when compared to the general population. Two hormones called aldosterone and brain natriuretic peptide (BNP), which have been shown to be abnormal…
- Trial name
- NCT04153136
- Testing
- Sacubitril-Valsartan 49-51Mg Oral Tablet
- Where
- United States
- Volunteers
- 39 people
- Sponsor
- Massachusetts General Hospital
Heart Failure
A Real-world Study to Compare the Effectiveness of Sacubitril/Valsartan Versus ACEi/ARB in HFrEF Patients
This was a retrospective, observational, comparative cohort study using secondary data from electronic health records (EHR) from a local health unit that provides primary, secondary and tertiary care to a resident population in…
- Trial name
- NCT07376265
- Where
- United States
- Volunteers
- 1,249 people
- Sponsor
- Novartis Pharmaceuticals
Sacubitril/Valsartan, Prosthetic Heart Valve
Sacubitril/Valsartan in Patients With Prosthetic Heart Valves With Heart Failure and Reduced Ejection Fraction
This study aims to evaluate the effect of sacubitril/valsartan in patients with prosthetic heart valves with heart failure with reduced ejection fraction (HFrEF).
- Conditions
- Sacubitril/Valsartan, Prosthetic Heart Valve, Heart Failure, Reduced Ejection Fraction
- Trial name
- NCT07192341
- Testing
- Sacubitril/Valsartan, Conventional anti-heart failure therapy
- Where
- Egypt
- Volunteers
- 220 people
- Sponsor
- Kafrelsheikh University
Heart Failure With Reduced Ejection Fraction, Heart Failure
STEPwise De-escalation and Optimizing Withdrawal of ARNI and SGLT2i in Normalized Heart Failure
This is a multicenter, randomized, open-label pilot study to evaluate whether stepwise withdrawal of two heart failure medications-angiotensin receptor-neprilysin inhibitor (ARNI) and sodium-glucose cotransporter-2 inhibitor…
- Conditions
- Heart Failure With Reduced Ejection Fraction, Heart Failure, Ventricular Dysfunction, Left
- Trial name
- STEP-DOWN HF (NCT07631156)
- Testing
- Stepwise Withdrawal of ARNI and SGLT2i, Continued Guideline-Directed Medical Therapy
- Where
- 5 sites in South Korea
- Volunteers
- 80 people
- Sponsor
- Kyungsub Song
Chronic Heart Failure With Reduced Ejection Fraction
randOmized stUdy Using acceleromeTry to Compare Sacubitril/valsarTan and Enalapril in Patients With Heart Failure
The purpose of this randomized, actively controlled, double-blind study with prospective data collection was to assess differences between sacubitril/valsartan versus enalapril in increasing exercise capacity and non-sedentary…
- Trial name
- OUTSTEP-HF (NCT02900378)
- Testing
- LCZ696 (Sacubitril/Valsartan), Enalapril
- Where
- 119 sites in Belgium, Bulgaria and 17 more
- Volunteers
- 621 people, healthy volunteers welcome
- Sponsor
- Novartis Pharmaceuticals
Heart Failure With Reduced Ejection Fraction, Cognitive Impairment, Mild
[11C]PS13 PET Imaging of Neuroinflammation in Heart Failure With Reduced Ejection Fraction
Heart failure reduces the amount of blood the heart pumps, which can lead to memory and thinking problems in many patients. One possible reason is that heart failure triggers brain inflammation, a process in which certain brain…
- Conditions
- Heart Failure With Reduced Ejection Fraction, Cognitive Impairment, Mild, Neuroinflammation, Vascular Contributions to Cognitive Impairment and Dementia (VCID)
- Trial name
- NEURO-HF (NCT07856043)
- Testing
- [11C]PS13: [carbon-11]PS13; COX-1 PET radioligand, Sacubitril-Valsartan
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- Stony Brook University
Myocardial Infarction, Hypertension
Sacubitril/Valsartan Versus Valsartan for Hypertensive Patients With Acute Myocardial Infarction
Studies have demonstrated that the early initiation of ACEI/ARB to patients with acute myocardial infarction is beneficial, especially in patients combined with reduced LVEF or mild-moderate heart failure.
- Trial name
- NCT05060588
- Testing
- Sacubitril/Valsartan 49/51mg/Tab, Valsartan 80mg/Tab
- Where
- China
- Volunteers
- 200 people
- Sponsor
- Qingdao Central Hospital
Bioequivalence Study
A Bioequivalence Study of Sacubitril/Valsartan Film-coated Tablets Under Fasting Conditions
Primary objective is to is to evaluate the bioequivalence of two formulations
- Trial name
- NCT06273254
- Testing
- Sacubitril and Valsartan Tablets 49mg/51mg, Entresto® (Sacubitril and Valsartan Tablets 49mg/51mg)
- Where
- Thailand
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- Viatris Inc.
Heart Failure
Efficacy and Safety of Sacubitril/Valsartan in African American Patients With Heart Failure With Reduced Ejection Fraction
There is limited long-term evidence specific to AAs with HFrEF on sacubitril/valsartan therapy. Plasma NT-proBNP levels are lower in AA individuals as compared to Caucasian individuals in general.
- Trial name
- NCT05168787
- Testing
- sacubitril/valsartan
- Where
- United States
- Volunteers
- 6,558 people
- Sponsor
- Methodist Health System
Heart Failure
Differential Vascular and Endocrine Effects of Valsartan/Sacubitril in Heart Failure With Reduced Ejection Fraction
The objective of this study is to evaluate whether valsartan/sacubitril leads to a superior improvement in endothelial function and endocrine status compared to valsartan alone.
- Trial name
- VASCEND (NCT03168568)
- Where
- Switzerland
- Volunteers
- 79 people
- Sponsor
- University of Zurich
Heart Failure
Sacubitril/Valsartan in Left Ventricular Assist Device Recipients
The primary objective of this prospective randomised study is to assess the safety and tolerability of sacubitril/valsartan compared with standard of care used for treating BP in patients that have been implanted with the Heart…
- Trial name
- ENVAD-HF (NCT04103554)
- Testing
- Sacubitril-Valsartan, Standard of care
- Where
- 6 sites in Croatia, Czechia and 2 more
- Volunteers
- 60 people
- Sponsor
- University of Zagreb
Healthy Volunteers
A Bioequivalence Study of Sacubitril/Valsartan Film-coated Tablets Under Fasting Conditions
To evaluate the bioequivalence between two formulations of sacubitril/valsartan 24 mg/26 mg film-coated tablets, Entresto 50 mg (Reference) and Sacubitril and Valsartan Sodium Tablets 24 mg/26 mg (Test), after a single oral dose…
- Trial name
- NCT06193187
- Testing
- Sacubitril and Valsartan Sodium Tablets 24 mg/26 mg, Entresto 50 mg
- Where
- Thailand
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- Dr. Reddy's Laboratories (Thailand) Limited
Hypertension
A Real-world Study of the Effectiveness of Angiotensin Receptor-Neprilysin Inhibitor Therapy in Hypertensive Patients in the United Arab Emirates
The aim of this study is to evaluate the real-world effectiveness of ARNi (sacubitril/valsartan) therapy and antihypertensive monotherapy in reducing blood pressure in hypertensive patients residing in the United Arab Emirates.
- Trial name
- REAL-HTN (NCT07465666)
- Where
- 4 sites in United Arab Emirates
- Volunteers
- 500 people
- Sponsor
- Novartis Pharmaceuticals